Scientific topics
Keywords
ITMO
Amélie Bonnefond PhD Human Genetics
Course and current status
EDUCATION & QUALIFICATIONS
2014 HDR (‘Habilitation à Diriger les Recherches’ that is an accreditation to supervise research) - Lille University (Lille, France)
2007 - 2010 PhD in Human Genetics with honors; Thesis entitled “Genetics of glucose control” under the guidance of Dr Martine Vaxillaire - Lille University (Lille, France)
2006 - 2007 MSc in Human Biology and Health; Thesis entitled “MYEOV is a new prognostic factor in multiple myeloma” under the guidance of Dr Jérôme Moreaux - Montpellier II University (Montpellier, France)
2004 - 2007 Diploma of Agronomist – Montpellier SupAgro (Montpellier, France)
2002 - 2004 Post-secondary preparatory school (CPGE) / classes preparing for entrance examinations to the French “Grandes Ecoles” – option “Biology, Chemistry, Physics, Earth Science” - Champollion high school (Grenoble, France)
PROFESSIONAL EXPERIENCE
2024 - present Director of Research (DR1) Inserm / Team Leader – Inserm/CNRS unit #1283/8199 - Lille Pasteur Institute, Lille University, Lille University Hospital, EGID (Lille, France)
2020 - 2023 Director of Research (DR2) Inserm / Team Leader – Inserm/CNRS unit #1283/8199 - Lille Pasteur Institute, Lille University, Lille University Hospital, EGID (Lille, France)
2015 - present Honorary Senior Scientist – Section of Genomics of Common Disease - School of Public Health, Imperial College London (London, UK)
2012 - present Scientific director of the next-generation sequencing platform LIGAN (http://ligan.good.cnrs.fr/en/)
2014 - 2019 Senior Research Associate (CR1) Inserm – CNRS unit #8199 - Lille Pasteur Institute, Lille University, EGID (Lille, France)
2012 - 2014 Postdoctoral researcher – CNRS unit #8199 - Lille Pasteur Institute, Lille University, EGID (Lille, France)
2012 - 2013 Visiting postdoctoral researcher – Inserm unit #695, headed by Prof Michel Marre - Faculty of Medicine X. Bichat - Paris 7 University (Paris, France)
2011 - 2012 Postdoctoral researcher – Inserm unit #1122, headed by Dr Sophie Visvikis-Siest - Lorraine University (Nancy, France)
PRIZES / AWARD
2022-2027 Consolidator Grant Award from the European Research Council (ERC; 2,000,000€)
2021 Minkowski award from the European Association for the Study of Diabetes (EASD)
2018 Auguste Loubatières award from the Société Francophone du Diabète (French-speaking diabetes society)
2017 - 2022 Starting Grant Award from the European Research Council (ERC; 1,500,000€)
2015 - 2018 Excellence Award from Inserm
2017 Best poster prize of the Miami 2017 Winter Symposium Diabetes: Today’s Research – Tomorrow’s Therapies [“Expression and functional assessment of candidate type 2 diabetes susceptibility genes identify four new genes contributing to human insulin secretion”]
2013 Young Investigator Travel Grant Award of the American Diabetes Association's 73rd Scientific Sessions (in the amount of $1,000 USD)
2012 Rising Star prize of the European Association for the Study of Diabetes (EASD)
2010 Prize of the Association for the Study of Congenital Abnormalities (AEAC, ‘Association pour l’étude des anomalies congénitales’)
KEY ORAL PRESENTATIONS AS INVITED SPEAKER
- Amélie Bonnefond. GWAS and post-GWAS era in type 2 diabetes. Course of the the European Society of Human Genetics (ESHG)/University of Surrey, Ferrara, Italy, July 2022
- Amélie Bonnefond. Genetic of pediatric obesity: Where are we? International Meeting on Childhood and Adolescent Obesity and Diabetes 2022: Treatment, Verona, Italy, June 2022
- Amélie Bonnefond. Identification of new targets modulating insulin secretion through the hunt for rare genetic variants? European Islet Study Group workshop, Strasbourg, France, June 2022
- Amélie Bonnefond. Hunt for pathogenic variants in Type 2 diabetes through NGS. PerkinElmer - The Pathologist webinar, remotely, June 2022
- Amélie Bonnefond. How to interpret rare variants? Annual congress of the French Association for Diabetes (SFD, Société Francophone du diabète), Nice, France, March 2022
- Amélie Bonnefond. Epigenetics and type 2 diabetes in the cohort studies. Annual congress of the French Association for Diabetes (SFD, Société Francophone du diabète), Nice, France, March 2022
- Amélie Bonnefond. Molecular diagnosis of genetic forms of obesity: issues and challenges. Association Française d'Etude et de Recherche sur l'Obésité (AFERO), Remotely, January 2022
- Amélie Bonnefond. MGSD-MODY study: Focus on Maghreb. Annual congress of the Algerian Association for Diabetes, Remotely, October 2021
- Amélie Bonnefond. Hunt for rare variants and pretty little things in the genetics of diabetes. Minkowski Prize lecture, 57th annual congress of the European Association for the Study of Diabetes (EASD), Remotely, September 2021
- Amélie Bonnefond. Pathogenic variants in actionable genes linked with monogenic diabetes are associated with common type 2 diabetes. European Society of Human Genetics (ESHG) corporate satellite, Remotely, June 2021
- Amélie Bonnefond. New causes of rare, early-onset obesity. Journées Francophones de Nutrition (JFN) / Association Française d'Etude et de Recherche sur l'Obésité (AFERO), Remotely, November 2020
- Amélie Bonnefond. Using NGS to improve genetic diagnosis of type 2 diabetes and obesity in France and abroad. PerkinElmer – Upgrade my NGS, Hambourg, Germany, December 2019
- Amélie Bonnefond. Towards the genetic continuum between common type 2 diabetes and monogenic diabetes. 7th meeting of the EASD Study Group on Genetics of Diabetes (EASD-SGGD), Prague, Czech Republic, May 2019
- Amélie Bonnefond. The MGSD MODY study. 16th meeting of the Mediterranean Group for the Study of Diabetes (MGSD), Casablanca, Morocco, April 2019
- Amélie Bonnefond. What are the genetic tools to reclassify diabetes subtypes? Annual congress of the French Association for Diabetes (SFD, Société Francophone du diabète), Marseille, France, March 2019
- Amélie Bonnefond. Expression study of genes identified by GWAS for type 2 diabetes and obesity. NanoString European Summit, Bordeaux, France, October 2018
- Amélie Bonnefond. Detection of rare genetic events contributing to type 2 diabetes and obesity using SeqCap EZ system. Roche Sequencing Solutions - Sample Preparation EMEA User Meeting, Riga, Latvia, October 2018
- Amélie Bonnefond. The genetics of type 2 diabetes at the bedside. 54th annual congress of the European Association for the Study of Diabetes (EASD), Berlin, Germany, October 2018
- Amélie Bonnefond. Contribution of rare genetic variants to the risk of type 2 diabetes. 2nd German French Conference on Diabetes Research, Berlin, Germany, April 2018
- Amélie Bonnefond. Génome & Diabète : Les Liaisons Dangereuses. Loubatières award at the Annual congress of the French Association for Diabetes (SFD, Société Francophone du diabète), Nantes, France, March 2018
- Amélie Bonnefond. Methylation study advent: toward new path in type 2 diabetes pathophysiology. Webinar Illumina, Lille, France, November 2017
- Amélie Bonnefond. Mélatonine et diabète de type 2 : contribution de la génétique. 34th Annual Congress of the French Society of Endocrinology (SFE, Société Française d’Endocrinologie), Poitiers, France, October 2017
- Amélie Bonnefond. Génétique du diabète de type 2 - Encore une ouverture ? 34th Annual Congress of the French Society of Endocrinology (SFE, Société Française d’Endocrinologie), Poitiers, France, October 2017
- Amélie Bonnefond. Post-GWAS functional analyses of variants (and proxy genes) associated with type 2 diabetes. 10th Conference of the International Society for Applied Biological Sciences on Forensic & Anthropologic Genetics and Mayo Clinic Lectures in Individualized Medicine, Dubrovnik, Croatia, June 2017
- Amélie Bonnefond. Post-GWAS functional analyses of variants (and proxy genes) associated with type 2 diabetes. Seminar Series at Max Planck Institute for Metabolism Research, Cologne, Germany, May 2017
- Amélie Bonnefond. The chronobiology of pancreatic beta cells – Focus on melatonin. Annual congress of the French Association for Diabetes (SFD, ‘Société Francophone du diabète’), Lille, France, March 2017
- Amélie Bonnefond. Genetics of obesity. Symposium “Obesity and kidney” organized by the French Academy of Medicine, Paris, France, March 2017
- Amélie Bonnefond. Post-GWAS functional analyses of rare and frequent variants associated with diabetes. BRC Genomics Seminar Series at Imperial College London, London, UK, December 2016
- Amélie Bonnefond. From genome-wide association studies to physiology: the example of melatonin pathway… a long unfinished journey. Seminar of the ‘Oxford Centre for Diabetes, Endocrinology and Metabolism’, Oxford, UK, May 2016
- Amélie Bonnefond. What have genetic events in type 2 diabetes brought to diabetes pathophysiology? Annual congress of the French Association for Ophthalmology (Société Française d’Ophtalmologie), Paris, France, May 2016
- Amélie Bonnefond. Rare and common genetic events in type 2 diabetes: what have they brought to diabetes pathophysiology? Seminar of the CSS-Mendel Institute, Roma, Italy, November 2015
- Amélie Bonnefond. Genetics of severe forms of obesity: an update. IMSS XXIV Foro Nacional de Investigación, Oaxtepec Morelos, Mexico, November 2015
- Amélie Bonnefond. Use of whole-exome sequencing & targeted sequencing in metabolic disorders. ‘Roche NGS library day’ (Roche), Paris, France, September 2015
- Amélie Bonnefond. Functional Exploration of Type 2 Diabetes-associated Genes. 75th Scientific Sessions of the American Diabetes Association (ADA), Boston, USA, June 2015
- Amélie Bonnefond. Genetics of the gut and link with type 2 diabetes. ‘Lilly Diabetes day’ (Lilly), Paris, France, January 2015
- Amélie Bonnefond. Where is the missing heritability in type 2 diabetes and obesity? The impact of rare genetic variants. Diabetes Dialogue “Hot Topics session” (Novo Nordisk), Madrid, Spain, December 2014
- Amélie Bonnefond. Genetics and biochemistry of disease causing mutations. Annual Summer School on Diabetes and Metabolism (University of Copenhagen / Novo Nordisk), Ebberup, Denmark, September 2014
- Amélie Bonnefond. Challenges in diagnosing neonatal diabetes. ICE/ENDO 2014 (16th International Congress of Endocrinology in combination with the Endocrine Society’s 96th annual meeting & expo), Chicago, USA, June 2014
- Amélie Bonnefond. Next generation sequencing to study rare and common variation in diabetes. 3rd Next Generation Sequencing course of the European School of Genetic Medicine, associated with the European Society of Human Genetics (ESHG), Bertinoro, Italy, May 2014
- Amélie Bonnefond. Exome sequencing to study rare and common variation in diabetes. 2nd Next Generation Sequencing course of the European School of Genetic Medicine, associated with the European Society of Human Genetics (ESHG), Bertinoro, Italy, May 2013
- Amélie Bonnefond. Impact of low-frequency variants into type 2 diabetes and obesity. Canadian Symposium, Annual congress of the French Association for Diabetes (SFD, ‘Société Francophone du diabète’), Montpellier, France, Mars 2013
- Amélie Bonnefond. Rare genetic events and metabolic diseases. Rising Star award lecture, 48th annual congress of the European Association for the Study of Diabetes (EASD), Berlin, Germany, October 2012
- Amélie Bonnefond. Rare MTNR1B variants impairing melatonin MT2 receptor function contribute to type 2 diabetes. 3rd meeting of the EASD Study Group on Genetics of Diabetes (EASD-SGGD), Bratislava, Slovakia, September 2011
PEER-REVIEWING FOR INTERNATIONAL JOURNALS
Nature Medicine – Nature Reviews Endocrinology – Cell – Cell Metabolism – Lancet Diabetes & Endocrinology – American Journal of Human Genetics – Diabetes Care – Journal Of The American Society Of Nephrology – Molecular Psychiatry – Diabetes – PLoS Genetics – Diabetologia – The Lancet Child & Adolescent Health – Communications Biology – Journal of Pineal Research – International Journal of Obesity – Human Molecular Genetics – Human Mutation – Molecular Metabolism – European Journal of Human Genetics – Obesity – Obesity Facts – Scientific Reports – Molecular Genetics and Metabolism – PLoS One – Diabetic Medicine – Endocrine – Clinical Genetics – Journal of Hypertension – Surgery for Obesity and Related Diseases – Diabetes & Metabolism – Journal of Diabetes – Translational Research – Expert Review of Molecular Diagnostics – International Journal of Molecular Sciences – BMC Medical Genetics – Gene – Hormone Research in Pediatrics – Genetic Testing and Molecular Biomarkers – Molecular Genetics & Genomic Medicine – Renal Failure – Meta Gene – Annals of Human Genetics – DNA and Cell BiologyScientific summary
So far, my scientific career has been focused on the dissection of the genetic etiologies of type 2 diabetes (T2D), obesity and cardiovascular diseases in order to elucidate their physiology towards a better stratification of the patients and a putative identification of new drugs towards more personalized medicine.
My achievements and expertise have been:
I/ Genome-wide association studies (GWAS) or targeted association studies of quantitative traits to identify novel loci associated with risk of T2D/obesity/cardiovascular disease;
II/ Genetic and functional evaluations of the contribution of rare variants in genes of interest (identified via GWAS, animal or familial studies), to either monogenic diabetes/obesity or to common T2D/obesity risk;
III/ Impact of clonal hematopoiesis on risk of T2D and vascular complications;
IV/ Next-generation sequencing and identification of new mutations or genes involved in rare and common forms of diabetes and obesity
